Plant Name: Curcuma aromatica
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| TDP1; PTGES; HSD17B3; NOS2; ALOX15; ALDH1A1; USP2; BRCA1; | |
| CACNA1C; | |
| PRKCE; GSK3B; MAPK1; EGFR; MAP2K1; MAP2K7; MAP3K7; | |
| CA2; CA1; CA12; CA9; CA13; CA5B; CA7; CA4; CA6; | |
| AR; NR3C1; | |
| ALOX5; MAOA; | |
| BACE1; | |
| MMP9; ANPEP; | |
| TLR9; | |
| HIF1A; RELA; | |
| EP300; | |
| HTT; NFE2L2; LMNA; SHBG; SERPINA6; F3; MAPT; APP; SIGMAR1; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Bromodomain | EP300 | Histone acetyltransferase p300 | Q09472 | CHEMBL3784 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PTGES | Prostaglandin E synthase | O14684 | CHEMBL5658 |
| Enzyme_unclassified | HSD17B3 | Estradiol 17-beta-dehydrogenase 3 | P37058 | CHEMBL4234 |
| Enzyme_unclassified | NOS2 | Nitric oxide synthase, inducible | P35228 | CHEMBL4481 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | ANPEP | Aminopeptidase N | P15144 | CHEMBL1907 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | PRKCE | Protein kinase C epsilon | Q02156 | CHEMBL3582 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Q02750 | CHEMBL3587 |
| Protein Kinase | MAP2K7 | Dual specificity mitogen-activated protein kinase kinase 7 | O14733 | CHEMBL3530 |
| Protein Kinase | MAP3K7 | Mitogen-activated protein kinase kinase kinase 7 | O43318 | CHEMBL5776 |
| Toll-like and Il-1 receptors | TLR9 | Toll-like receptor 9 | Q9NR96 | CHEMBL5804 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | RELA | Nuclear factor NF-kappa-B p65 subunit | Q04206 | CHEMBL5533 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | NFE2L2 | Nuclear factor erythroid 2-related factor 2 | Q16236 | CHEMBL1075094 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | SHBG | Testis-specific androgen-binding protein | P04278 | CHEMBL3305 |
| Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
| Voltage-gated calcium channel | CACNA1C | Voltage-gated L-type calcium channel alpha-1C subunit | Q13936 | CHEMBL1940 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.119E-09 | 4.614E-06 | ANPEP, AR, BRCA1, CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9, EP300, MMP9, NR3C1 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 7.347E-08 | 6.827E-05 | ALDH1A1, AR, SHBG |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.499E-07 | 1.126E-04 | CA2, CA7, EGFR, HIF1A, HTT, MAP2K7, MAPK1, NPSR1 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 4.613E-07 | 3.011E-04 | CA2, CA7, CACNA1C, EGFR, HIF1A, HTT, MAP2K7, MAPK1, NPSR1, PRKCE |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 8.060E-07 | 3.891E-04 | BRCA1, EGFR, MAPK1, NFE2L2, NOS2, NR3C1, PRKCE, RELA |
| BP | GO:0009987; cellular process | GO:1901522; positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 9.114E-07 | 3.891E-04 | EP300, HIF1A, NFE2L2, RELA |
| CC | GO:0044464; cell part | GO:0005641; nuclear envelope lumen | 1.021E-06 | 4.248E-04 | ALOX5, APP, PTGES |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 1.528E-06 | 5.385E-04 | APP, EGFR, MAPT |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 2.990E-06 | 8.348E-04 | GSK3B, HTT, MAPT |
| BP | GO:0065007; biological regulation | GO:0043085; positive regulation of catalytic activity | 3.205E-06 | 8.808E-04 | ALDH1A1, APP, EGFR, F3, GSK3B, HIF1A, MAP2K1, MAP2K7, MAP3K7, MAPK1, MAPT, NOS2, PRKCE, TLR9, TSHR |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 3.429E-06 | 9.218E-04 | AR, CYP3A4, NR3C1, SERPINA6, SHBG |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.369E-06 | 1.106E-03 | ALOX15, ALOX5, CYP19A1, CYP2C9, CYP3A4, NOS2 |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 4.778E-06 | 1.182E-03 | ALOX15, BRCA1, GSK3B, HIF1A, HTT, MAP2K7, MAPK1, MAPT, MMP9, PRKCE |
| BP | GO:0009987; cellular process | GO:1901224; positive regulation of NIK/NF-kappaB signaling | 4.845E-06 | 1.185E-03 | APP, EGFR, MAP3K7, RELA |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 5.164E-06 | 1.249E-03 | CA2, CA7, PRKCE |
| MF | Unclassified; | GO:0004708; MAP kinase kinase activity | 8.184E-06 | 1.764E-03 | MAP2K1, MAP2K7, MAPK1 |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 8.327E-06 | 1.778E-03 | AR, BRCA1, HTT, LMNA, RELA |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.036E-05 | 2.089E-03 | CA2, CA4, CA9, EGFR, TLR9, TSHR |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.050E-05 | 2.097E-03 | EGFR, MAPK1, MMP9, NFE2L2, RELA |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 1.372E-05 | 2.575E-03 | ALDH1A1, ALOX15, APP, CYP19A1, CYP3A4, HIF1A, HSD17B3, MAOA |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 1.812E-05 | 3.131E-03 | APP, CA2, CA7, CACNA1C, HIF1A, HTT, MAPK1, NPSR1, PRKCE |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.954E-05 | 3.325E-03 | CA2, CA7, CACNA1C, HTT, NPSR1, PRKCE |
| BP | GO:0050896; response to stimulus | GO:0033590; response to cobalamin | 2.129E-05 | 3.485E-03 | EGFR, RELA |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.129E-05 | 3.485E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0009894; regulation of catabolic process | 2.623E-05 | 4.080E-03 | EGFR, EP300, GSK3B, HIF1A, HTT, MAP3K7, MAPT, NFE2L2, NOS2, PRKCE, RELA |
| BP | GO:0009987; cellular process | GO:0010821; regulation of mitochondrion organization | 3.118E-05 | 4.713E-03 | GSK3B, HIF1A, HTT, LMNA, MAPT, MMP9 |
| BP | GO:0048511; rhythmic process | GO:0007623; circadian rhythm | 3.202E-05 | 4.719E-03 | EGFR, EP300, GSK3B, NOS2, USP2 |
| BP | GO:0050896; response to stimulus | GO:0032870; cellular response to hormone stimulus | 3.526E-05 | 5.019E-03 | AR, EGFR, NFE2L2, NR3C1, PRKCE, RELA, TSHR |
| BP | GO:0065007; biological regulation | GO:0051092; positive regulation of NF-kappaB transcription factor activity | 3.680E-05 | 5.136E-03 | APP, AR, MAP3K7, RELA, TLR9 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 3.754E-05 | 5.207E-03 | EP300, GSK3B, HIF1A, HTT |
| BP | GO:0007610; behavior | GO:0007611; learning or memory | 3.879E-05 | 5.346E-03 | APP, EGFR, HIF1A, HTT, MAPK1, MAPT |
| BP | GO:0009987; cellular process | GO:0090170; regulation of Golgi inheritance | 4.250E-05 | 5.542E-03 | MAP2K1, MAPK1 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 4.250E-05 | 5.542E-03 | APP, TLR9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.250E-05 | 5.542E-03 | CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 4.430E-05 | 5.699E-03 | BRCA1, CA2, EP300, MAPK1 |
| BP | GO:0032502; developmental process | GO:0048732; gland development | 4.569E-05 | 5.818E-03 | AR, CYP19A1, EGFR, MAP2K1, MAPK1, RELA |
| BP | Unclassified; | GO:0051279; regulation of release of sequestered calcium ion into cytosol | 5.465E-05 | 6.761E-03 | CACNA1C, HTT, NPSR1, PRKCE |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 5.748E-05 | 6.955E-03 | CYP19A1, CYP3A4, HSD17B3 |
| BP | GO:0009987; cellular process | GO:1900034; regulation of cellular response to heat | 5.749E-05 | 6.955E-03 | EP300, GSK3B, MAPK1, MAPT |
| CC | GO:0044464; cell part | GO:0030424; axon | 6.380E-05 | 7.509E-03 | APP, BACE1, CA2, HTT, MAPK1, MAPT |
| BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 6.666E-05 | 7.762E-03 | AR, EGFR, NR3C1, PRKCE |
| BP | GO:0008152; metabolic process | GO:0061370; testosterone biosynthetic process | 7.071E-05 | 8.062E-03 | CYP19A1, HSD17B3 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 7.843E-05 | 8.707E-03 | EGFR, MAPK1, MMP9 |
| BP | GO:0008152; metabolic process | GO:0090322; regulation of superoxide metabolic process | 7.843E-05 | 8.707E-03 | EGFR, MAPT, NFE2L2 |
| BP | GO:0065007; biological regulation | GO:0032092; positive regulation of protein binding | 8.048E-05 | 8.851E-03 | APP, EP300, GSK3B, MMP9 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 8.637E-05 | 9.311E-03 | HIF1A, MAPT, NR3C1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.767E-20 | 3.848E-16 | CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.186E-16 | 3.469E-12 | CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.361E-15 | 1.714E-11 | CA1, CA12, CA13, CA2, CA4, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.253E-20 | 1.057E-17 | CA12; CA1; CA5B; CA2; CA4; CA7; CA6; CA9; CA13 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.603E-10 | 3.889E-08 | CYP2C9; APP; MAP2K1; MAOA; ALOX5; ALOX15; MAPK1; CACNA1C |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 3.091E-09 | 1.741E-07 | GSK3B; AR; MAP2K1; EP300; MAPK1; RELA; EGFR |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 6.383E-08 | 2.157E-06 | AR; GSK3B; MAP2K1; NOS2; EP300; MAPK1; HIF1A; MMP9; EGFR; RELA |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 8.646E-09 | 3.653E-07 | MAP2K1; NOS2; EP300; MAPK1; HIF1A; RELA; EGFR |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.901E-07 | 6.780E-06 | MAP2K1; MAPK1; MAPT; CACNA1C; MAP2K7; MAP3K7; RELA; EGFR |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.866E-07 | 6.780E-06 | GSK3B; MAP2K1; MAPK1; MAP2K7; MAP3K7; RELA |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 3.210E-07 | 6.780E-06 | MAP2K1; TLR9; MAPK1; MAP2K7; MAP3K7; RELA |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 3.998E-07 | 7.507E-06 | MAP2K1; MAPK1; MAP2K7; MAP3K7; MMP9; RELA |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 3.068E-06 | 5.185E-05 | GSK3B; MAP2K1; MAPK1; MAP2K7; EGFR |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 3.831E-06 | 5.396E-05 | MAP2K1; MAPK1; CACNA1C; MAP2K7; EGFR |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 6.006E-06 | 7.250E-05 | GSK3B; MAP2K1; EP300; MAPK1; MAP2K7; RELA |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 4.749E-06 | 6.174E-05 | BACE1; APP; GSK3B; MAPK1; CACNA1C; MAPT |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.120E-05 | 1.183E-04 | MAP2K1; PRKCE; EP300; MAPK1; BRCA1; MMP9; EGFR |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.252E-05 | 1.216E-04 | MAP2K1; EP300; MAPK1; CACNA1C; RELA; TSHR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.831E-06 | 5.396E-05 | MAP2K1; MAPK1; MMP9; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.003E-05 | 1.130E-04 | GSK3B; MAP2K1; MAPK1; EGFR |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.367E-05 | 1.216E-04 | NOS2; ALOX5; MAPK1; MAP3K7; RELA |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.367E-05 | 1.216E-04 | GSK3B; MAP2K1; EP300; MAPK1; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.483E-05 | 1.254E-04 | GSK3B; MAP2K1; MAPK1; MAP2K7; RELA |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.352E-05 | 1.757E-04 | MAP2K1; MAPK1; MAP2K7; MAP3K7; RELA |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.816E-05 | 2.182E-04 | MAP2K1; EP300; MAPK1; MMP9; RELA |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.027E-05 | 1.631E-04 | CYP2C9; ALOX5; ALOX15; PTGES |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 2.599E-05 | 1.757E-04 | MAP2K1; EP300; MAPK1; HIF1A |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.599E-05 | 1.757E-04 | MAP2K1; MAPK1; RELA; EGFR |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 2.599E-05 | 1.757E-04 | MAP2K1; EP300; MAPK1; CACNA1C |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.668E-05 | 2.182E-04 | GSK3B; MAP2K1; MAPK1; RELA |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.759E-05 | 1.793E-04 | MAP2K1; MAPK1; HIF1A; EGFR |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 3.873E-05 | 2.182E-04 | GSK3B; MAP2K1; MAPK1; RELA |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 3.873E-05 | 2.182E-04 | NOS2; MAPK1; MAP3K7; RELA |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 9.778E-05 | 4.860E-04 | NOS2; TLR9; EP300; MAPK1; RELA |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.377E-04 | 6.124E-04 | PRKCE; MAPK1; F3; RELA |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 4.086E-05 | 2.228E-04 | EP300; MAPK1; MAP3K7; EGFR |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.274E-04 | 6.124E-04 | MAP2K1; MAPK1; MMP9; EGFR |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.768E-04 | 7.457E-04 | GSK3B; EP300; MAP2K7; MAP3K7; RELA |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.325E-04 | 6.124E-04 | GSK3B; MAP2K1; EP300; MAPK1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.809E-04 | 7.457E-04 | MAP2K1; MAPK1; HIF1A; MMP9; EGFR |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.472E-04 | 9.946E-04 | GSK3B; MAP2K1; MAPK1; BRCA1; RELA; EGFR |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.377E-04 | 6.124E-04 | MAP2K1; MAPK1; HIF1A; EGFR |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.833E-04 | 1.041E-03 | CYP2C9; NOS2; MAOA; ANPEP; ALOX5; ALOX15; ALDH1A1; HSD17B3; CYP3A4; CYP19A1; PTGES |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.542E-04 | 6.681E-04 | NOS2; TLR9; MAPK1; RELA |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 2.671E-04 | 1.003E-03 | MAP2K1; PRKCE; MAPK1; CACNA1C |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.671E-04 | 1.003E-03 | MAP2K1; PRKCE; MAPK1; RELA |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.952E-04 | 1.391E-03 | GSK3B; MAPK1; RELA; EGFR |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 3.952E-04 | 1.391E-03 | MAP2K1; EP300; MAPK1; EGFR |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 4.300E-04 | 1.428E-03 | GSK3B; TLR9; MAP3K7; RELA |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.798E-04 | 1.502E-03 | MAP2K1; LMNA; MAPK1; RELA |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 7.558E-04 | 2.165E-03 | MAP2K1; MAPK1; CACNA1C; EGFR |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 9.291E-04 | 2.492E-03 | MAP2K1; PRKCE; MAPK1; CACNA1C |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.357E-03 | 3.528E-03 | TLR9; EP300; MAP3K7; RELA |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.412E-03 | 3.614E-03 | GSK3B; MAP2K1; MAPK1; RELA |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.872E-03 | 4.456E-03 | GSK3B; MAP2K1; MAPK1; EGFR |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 2.856E-03 | 6.546E-03 | MAP2K1; MAPK1; RELA; EGFR |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 4.169E-04 | 1.428E-03 | MAP2K1; MAPK1; EGFR |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 7.374E-04 | 2.149E-03 | MAP2K1; MAPK1; MAP2K7 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 3.017E-03 | 6.799E-03 | MAP2K1; MAPK1; CACNA1C |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.640E-04 | 1.003E-03 | PRKCE; MAPK1; CACNA1C |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 6.462E-04 | 1.916E-03 | MAP2K1; MAPK1; EGFR |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 9.068E-04 | 2.472E-03 | MAP2K1; MAPK1; RELA |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.866E-03 | 6.546E-03 | GSK3B; PRKCE; RELA |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 4.393E-04 | 1.428E-03 | MAP2K1; MAPK1; RELA |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 8.364E-04 | 2.317E-03 | MAP2K1; MAPK1; EGFR |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.824E-03 | 4.404E-03 | MAP2K1; PRKCE; MAPK1 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 6.006E-03 | 1.253E-02 | GSK3B; EP300; MAP3K7 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 4.028E-03 | 8.840E-03 | AR; MAP2K1; MAPK1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 5.662E-03 | 1.211E-02 | GSK3B; MAP2K1; MAPK1 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 6.243E-03 | 1.287E-02 | MAP2K1; MAPK1; EGFR |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 6.006E-03 | 1.253E-02 | GSK3B; MAP2K1; MAPK1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 4.601E-03 | 9.969E-03 | GSK3B; MAOA; CACNA1C |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 5.626E-04 | 1.729E-03 | GSK3B; MAP2K1; MAPK1 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.557E-03 | 3.869E-03 | MAP2K1; MAPK1; EGFR |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.147E-02 | 2.154E-02 | NOS2; CACNA1C; EGFR |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 6.462E-04 | 1.916E-03 | CYP2C9; ALDH1A1; CYP3A4 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 1.130E-02 | 2.146E-02 | MAP2K1; MAOA; MAPK1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 4.393E-04 | 1.428E-03 | MAPK1; MAP3K7; RELA |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.457E-03 | 3.675E-03 | NOS2; MAPK1; RELA |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.695E-04 | 2.167E-03 | CYP2C9; MAOA; CYP3A4 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.623E-02 | 2.799E-02 | EP300; MAPK1; RELA |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 9.809E-04 | 2.590E-03 | NOS2; MAPK1; RELA |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.751E-02 | 2.990E-02 | MAP2K1; MAPK1; EGFR |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.818E-02 | 3.072E-02 | MAP2K1; MAPK1; EGFR |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.624E-04 | 1.474E-03 | HSD17B3; CYP3A4; CYP19A1 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 4.640E-05 | 2.450E-04 | MAP2K1; MAPK1; EGFR |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.950E-02 | 4.451E-02 | GSK3B; EP300; RELA |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.775E-05 | 2.957E-04 | CYP2C9; ALOX15; CYP3A4 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.689E-02 | 4.169E-02 | MAP2K1; MAPK1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 2.791E-02 | 4.288E-02 | NOS2; RELA |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 2.843E-02 | 4.328E-02 | MAPK1; CACNA1C |
| hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 2.538E-02 | 3.972E-02 | MAPK1; CACNA1C |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.440E-02 | 3.854E-02 | MAP3K7; RELA |
| hsa05414 | Dilated cardiomyopathy_Homo sapiens_hsa05414 | 2.295E-02 | 3.660E-02 | LMNA; CACNA1C |
| hsa04350 | TGF-beta signaling pathway_Homo sapiens_hsa04350 | 2.018E-02 | 3.279E-02 | EP300; MAPK1 |
| hsa04925 | Aldosterone synthesis and secretion_Homo sapiens_hsa04925 | 1.885E-02 | 3.154E-02 | PRKCE; CACNA1C |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.109E-02 | 3.394E-02 | NOS2; RELA |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.929E-02 | 3.195E-02 | CYP2C9; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.549E-02 | 2.727E-02 | CYP2C9; CYP3A4 |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 1.316E-02 | 2.418E-02 | MAOA; CACNA1C |
| hsa05410 | Hypertrophic cardiomyopathy (HCM)_Homo sapiens_hsa05410 | 1.973E-02 | 3.237E-02 | LMNA; CACNA1C |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.469E-02 | 2.614E-02 | CA2; CYP3A4 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.066E-02 | 2.070E-02 | MAPK1; HIF1A |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 1.066E-02 | 2.070E-02 | MAP2K1; MAPK1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.100E-02 | 2.113E-02 | MAP2K1; MAPK1 |
| hsa04622 | RIG-I-like receptor signaling pathway_Homo sapiens_hsa04622 | 1.430E-02 | 2.572E-02 | MAP3K7; RELA |
| hsa05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC)_Homo sapiens_hsa05412 | 1.589E-02 | 2.769E-02 | LMNA; CACNA1C |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.354E-02 | 2.460E-02 | RELA; EGFR |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.242E-02 | 2.307E-02 | MAPK1; RELA |
| hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 7.500E-03 | 1.491E-02 | NOS2; MAOA |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 7.500E-03 | 1.491E-02 | ALOX5; CYP19A1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 7.212E-03 | 1.468E-02 | MAOA; RELA |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 3.734E-03 | 8.304E-03 | MAP2K1; MAPK1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.574E-03 | 6.041E-03 | MAP2K1; MAPK1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.620E-03 | 3.967E-03 | CA2; CA4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; NOS2 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | TLR9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; HIF1A; CA1; CA9; MAPK1; MMP9; EGFR; APP; TLR9; NR3C1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | CACNA1C |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | EGFR; EGFR; EGFR |
| I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | CACNA1C |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; EGFR |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; CA9; EGFR; EGFR; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | PRKCE; TLR9 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP; NPSR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| I00-I99: Diseases of the circulatory system | Ischemic reperfusion injury | I00-I99 | PRKCE |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NR3C1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; CA9; MAPK1; MMP9; EGFR; TLR9 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; APP; MAOA; PTGES; MAPT |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | TLR9; NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1 |
| NA: NA | Non-infectious rhinitis | NA | NR3C1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | TLR9 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; NOS2; SERPINA6; NR3C1 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; NR3C1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Endotoxic shock | R57.8 | NOS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | NR3C1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | NFE2L2; EGFR; EGFR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; EGFR |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; TLR9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | NOS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; MAOA; NR3C1 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | CACNA1C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TLR9 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | TLR9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; TLR9 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
| H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR; F3 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; NOS2 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | TLR9 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6 |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| NA: NA | Obstructive airway diseases | NA | SERPINA6 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | NFE2L2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; NR3C1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic kidney disease | E11.22 | NOS2 |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; EGFR; ANPEP |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; NOS2 |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; NR3C1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3 |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; EGFR; APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR; TLR9 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | NOS2 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; EGFR; EGFR; TLR9 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; NOS2; SERPINA6; TLR9; TLR9; NR3C1; NR3C1; NR3C1; NR3C1 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; TLR9 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Mantle cell lymphoma | C81-C86, C85.7, C90.0, C91-C95 | MAP3K7 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; NR3C1; NR3C1; NR3C1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5; NR3C1 |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | TLR9 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |